Financial Data and Key Metrics Changes - Net revenues for Q1 2025 were $5.4 million, approximately 27% lower than Q1 2024 [3] - Operating expenses were $7.7 million, showing a 33% improvement over Q1 2024 [4] - Operating loss was $2.3 million, a 45% improvement over Q1 2024 [4] - Net loss was $3.1 million, representing a 29% improvement over Q1 2024 [4] - Basic and diluted earnings per share were a loss of $0.21, an improvement of $0.25 per share over Q1 2024 [4] Business Line Data and Key Metrics Changes - The company is focusing on margin-generating clients and managing lower-margin clients to drop off [3][4] - The TPA market in the U.S. is valued at $150 billion, with a forecasted annual growth of 12.1% through 2031 [8] Market Data and Key Metrics Changes - The company is positioned to partner with employers adopting self-funded health insurance, which is a growing trend due to rising healthcare costs [5][6] - Employers can see savings of up to 10% by moving to a self-funded model managed by a TPA [6] Company Strategy and Development Direction - The company aims to deliver affordable and intelligent healthcare solutions, with a strong pipeline of business for the second half of 2025 [11] - The recent appointment of Dallas Scripp as COO is part of the strategy to strengthen leadership and drive growth initiatives [12] - The company is focused on achieving profitability and cash flow positivity within the year [12][14] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in signing new business in Q1 but emphasizes a strong pipeline for the second half of 2025 [15][19] - The company is working on cost reduction initiatives and operational efficiencies to reduce cash burn and improve profitability [21][22] - The rollout of the Empower member portal is expected to enhance customer experience and operational efficiency [23][25] Other Important Information - The company is rationalizing multiple portals into the Empara solution, which utilizes AI to improve member services [24][25] - The company is committed to reducing costs while enhancing customer service, creating a virtuous cycle for client acquisition [22] Q&A Session Summary Question: Why was new business not signed up as expected in Q1? - Management focused on turnaround efforts in 2024 and did not hire key sales personnel until May, impacting new business acquisition [16][17] Question: What are the potential for further cost reduction initiatives? - Management is working on rationalizing duplicative vendors and legacy contracts, which will provide additional savings [21][22] Question: Can you elaborate on the Empara portal and its benefits? - The Empara portal consolidates multiple applications and provides members with easy access to their benefit plans, improving efficiency and reducing call center demands [24][25]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40904 MARPAI, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation) Delaware 86-1916231 (IRS Employer Identification Number) For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

FOR IMMEDIATE RELEASE MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Marpai's turnaround momentum is building. Tampa, May 14, 2025, Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025. Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting ope ...

Marpai's turnaround momentum is buildingTAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025.Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting operating expenses and improving our bottom line signals wh ...

About Marpai, Inc. TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Marpai, Inc. (OTCQX: MRAI) is a technology platfo ...

The investor conference is in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025TAMPA, Fla., April 15, 2025 /PRNewswire/ -- Marpai, Inc. (OTCQX: MRAI),  a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and offers affordable, intelligent, healthcare solutions to self-funded employer health plans, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partne ...

Marpai, Inc. (OTCQX:MRAI) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Steve Johnson - Chief Financial Officer Damien Lamendola - Chief Executive Officer and Director John Powers - President Conference Call Participants Ian Cassel - IFCM Operator Good morning, and welcome to the Marpai Fourth Quarter and Full-Year 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation there will be an opportunity to ...

Financial Performance - Total revenue for the year ended December 31, 2024, was $28.2 million, a decrease of 24% from $37.2 million in 2023[151] - Net loss for 2024 was $22.1 million, a 23% improvement from a net loss of $28.8 million in 2023[168] - Adjusted EBITDA loss improved to $9.1 million in 2024 from a loss of $20.2 million in 2023, due to better resource utilization and expense reduction[171] Expenses - Cost of revenue for 2024 was $19.1 million, down 21% from $24.2 million in 2023, aligning with the decrease in revenue[153] - General and administrative expenses decreased by 33% to $12.8 million in 2024 from $19.2 million in 2023, resulting in savings of approximately $6.4 million[155] - Sales and marketing expenses dropped 73% to $1.8 million in 2024 from $6.6 million in 2023, reflecting a savings of about $4.8 million[156] - Research and development expenses fell by 98% to $29 thousand in 2024 from $1.3 million in 2023, due to a focus on eliminating certain development projects[158] Cash Flow and Financing - The company recognized a net cash used in operating activities of $15.2 million for the year ended December 31, 2024, compared to $15.7 million for 2023, reflecting a decrease of $591 thousand[191] - Net cash provided by financing activities increased to $10.7 million in 2024 from $5.1 million in 2023, primarily due to proceeds from private placements and the issuance of debentures[193] - The company financed its operations primarily through the sale of convertible notes, warrants, and common stock, as well as borrowing from various lenders[177] Impairments and Charges - The company recorded a goodwill and intangible asset impairment charge of $7.6 million in June 2024, reflecting a full impairment due to operational changes[160] - The company reported a net loss of $22.1 million for the year ended December 31, 2024, which was offset by non-cash items totaling $13.6 million and a decrease in net working capital items amounting to $6.7 million[191] Capital Transactions - The company entered into a securities purchase agreement on January 16, 2024, selling 1,322,100 shares at a price of $0.9201 per share, raising capital from insiders[183] - The company executed a debt reduction agreement on January 31, 2025, reducing the Base Purchase and Full Base Amount by $3 million, contingent on meeting specific criteria by December 31, 2024[179] - The company repaid $1.8 million to Libertas Funding, LLC in April 2024 to satisfy the Libertas Agreement, which involved selling future receipts totaling $2.2 million for a purchase price of $1.7 million[184] - The company issued Senior Secured Convertible Debentures for a principal sum of $11.83 million on April 15, 2024, with an option to redeem $5 million at its election[186] - The company recognized a gain of $3.0 million in its consolidated statements of operations as of December 31, 2024, following the fulfillment of reduction criteria under the AXA Amendment[179] Going Concern and Liquidity - The company has substantial doubt about its ability to continue as a going concern for the next twelve months due to liquidity concerns[182] Share-Based Compensation - The company accounts for share-based compensation in accordance with ASC Topic 718, recognizing expenses over the requisite service period, generally the vesting period of the grant[205] - The expected term of stock options granted to employees is estimated using the simplified method, averaging the vesting term and the original contractual term[207] - The fair value of share-based payment awards is calculated using the Black-Scholes option-pricing model, influenced by stock price, expected volatility, expected life, risk-free interest rate, and expected dividends[207] - The company evaluates convertible notes and debentures to determine if any embedded features require separate accounting as derivative financial instruments[209] - Changes in assumptions for share-based compensation may significantly impact future results of operations, with incremental costs recognized when incurred[208] - The company includes variable consideration in transaction prices only if it is probable that amounts will not be subject to significant reversals[204] - Share-based awards that vest based on performance conditions recognize expense when it is probable that the conditions will be met[208] - The company accounts for forfeitures of awards as they occur, impacting the share-based compensation expense[208] Accounting and Market Risk - Recent accounting pronouncements are discussed in Note 3 of the consolidated financial statements in the Annual Report[210] - There are no applicable quantitative and qualitative disclosures about market risk[211]

Financial Performance - Q4 2024 net revenues were $6.6 million, a decrease of $0.4 million, or 6.0% lower than Q3 2024[5] - Full year 2024 net revenues were $28.2 million, down $9.0 million, or 24.2% lower year over year[5] - Adjusted EBITDA for the year ended December 31, 2024 amounted to a loss of $9.1 million, an improvement from a loss of $20.2 million in 2023[4] - Net loss for the fiscal year was $22.1 million, an improvement of $6.7 million, or 23.2% lower year over year[5] - Basic and diluted earnings per share in Q4 2024 were ($0.08), an improvement of $0.22 per share compared to Q3 2024[5] - Net loss for the year ended December 31, 2024, was $22,088,000, an improvement from a net loss of $28,752,000 in 2023, representing a 23.3% reduction[22] - Adjusted EBITDA for the year ended December 31, 2024, was $(9,057,000), compared to $(20,181,000) in 2023, indicating a significant improvement of 55.1%[25] Operating Expenses and Cash Flow - Operating expenses for the fiscal year ended December 31, 2024 were $31.2 million, an improvement of $9.7 million, or 23.7% lower year over year[5] - Cash flows from operating activities resulted in a net cash used of $15,158,000 for 2024, slightly better than $15,749,000 in 2023[22] - Total cash, cash equivalents, and restricted cash at the end of the period decreased to $9,232,000 from $13,492,000 at the beginning of the period, reflecting a decrease of 31.7%[22] - Cash paid for interest in 2024 was $1,742,000, compared to no interest paid in 2023[23] Assets and Liabilities - Marpai's total current assets decreased to $11.9 million as of December 31, 2024, down from $17.1 million in 2023[18] - Total liabilities decreased to $40.6 million as of December 31, 2024, down from $45.1 million in 2023[18] Impairment and Depreciation - Impairment of goodwill and intangible assets increased to $7,588,000 in 2024 from $3,018,000 in 2023, indicating a rise of 151.5%[25] - Depreciation and amortization expenses decreased to $2,256,000 in 2024 from $3,897,000 in 2023, a reduction of 42.0%[25] Financing Activities - Proceeds from the issuance of convertible debentures amounted to $8,000,000 in 2024, with additional net cash provided by financing activities totaling $10,671,000[22] - The company reported a loss on debt extinguishment of $1,877,000 in 2024, with no such loss reported in 2023[25] Business Strategy - The company plans to introduce high-impact PBM-based products in the second half of 2025 to drive revenue growth[7] - The company is focused on streamlining costs while deploying innovative services, including the Empara Member Engagement Portal[7] Business Unit Sale - The company generated $227,000 from the sale of a business unit in 2024, down from $1,000,000 in 2023[22]

TAMPA, Fla., March 18, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a technology platform company and a disruptor in the $22 billion Third-Party Administrator ("TPA") market, is taking decisive action to revolutionize self-funded employer health plans. Today, Marpai announces a strategic collaboration with Empara, a healthcare technology innovator, and an immediate rollout of Empara's cutting-edge Health Engagement Platform.This dynamic move consolidates and replaces multiple ...